What is BeyondSpring Inc?
BeyondSpring Inc. is a clinical-stage biopharmaceutical company dedicated to the development of innovative cancer treatments. Its primary focus is on Plinabulin, a selective immunomodulating microtubule-binding agent that has successfully completed Phase III clinical trials for non-small cell lung cancer (NSCLC). The company is also exploring Plinabulin's efficacy in combination therapies with other agents, including PD-1 and CTLA-4 antibodies, as well as chemotherapy and radiation, for various oncological indications. BeyondSpring is further expanding its pipeline with three small molecule immune agents in preclinical development and a robust drug discovery platform. Founded in 2010 and headquartered in Florham Park, New Jersey, the company is strategically advancing its therapeutic candidates through rigorous clinical evaluation.
How much funding has BeyondSpring Inc raised?
BeyondSpring Inc has raised a total of $3.8M across 2 funding rounds:
Stock Offering
$3.5M
Debt
$350K
Stock Issuance/Offering (2017): $3.5M, investors not publicly disclosed
Debt (2020): $350K led by PPP
Key Investors in BeyondSpring Inc
PPP
Public-Private Partnership
What's next for BeyondSpring Inc?
With the recent major strategic investment and substantial total funding, BeyondSpring Inc. is poised to accelerate its development programs. The company's focus will likely be on advancing Plinabulin through regulatory pathways and potentially preparing for commercialization. Further investment in its preclinical immune agents and drug discovery platform suggests a long-term vision for sustained innovation in oncology. This capital infusion is critical for navigating the complex and lengthy process of drug development and market entry in the competitive biopharmaceutical landscape.
See full BeyondSpring Inc company page
